{"nctId":"NCT01382212","briefTitle":"A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis","startDateStruct":{"date":"2011-10"},"conditions":["End-Stage Renal Disease","Secondary Hyperparathyroidism"],"count":13,"armGroups":[{"label":"Paricalcitol","type":"EXPERIMENTAL","interventionNames":["Drug: paricalcitol"]}],"interventions":[{"name":"paricalcitol","otherNames":["ABT-358, Zemplar"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject must be receiving peritoneal dialysis or hemodialysis for at least 3 months prior to Screening\n* Subject is currently being diagnosed and/or treated for secondary hyperparathyroidism\n* For entry into the Dosing Period (for subjects that are naïve to Vitamin D Receptor \\[VDR\\] Activators or those who have completed a 2 to 12 week washout), the subject must meet the following laboratory criteria prior to enrollment:\n\n  * A corrected calcium value ≥ 8.2 and ≤ 10.4 mg/dL\n  * A phosphorus value ≤ 6.5 mg/dL\n  * An intact parathyroid hormone (iPTH) value \\> 300 pg/mL and less ≤ 2000 pg/mL\n\nExclusion Criteria:\n\n* Subject is expected or scheduled to receive a living donor kidney transplant within 3 months of Screening or is a kidney transplant patient requiring full immunosuppressant therapy\n* Subject is expected to stop peritoneal dialysis or hemodialysis within 4 months of Screening (per investigator discretion)\n* Subject has had a parathyroidectomy within 12 weeks prior to Screening\n* Subject has had symptomatic or significant hypocalcemia requiring VDR Activator therapy (i.e., calcitriol, paricalcitol, or doxercalciferol) within 2 months prior to Screening\n* Subject is taking maintenance calcitonin, bisphosphonates, glucocorticoids in an equivalent dose of greater than 5 mg prednisone daily, or other drugs known to affect calcium or bone metabolism within 4 to 8 weeks prior to Dosing\n* Subject is receiving cinacalcet at the time of Screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Hypercalcemia","description":"The percentage of subjects with hypercalcemia, defined as at least 2 consecutive post-baseline corrected calcium values \\> 10.2 mg/dL (2.55 mmol/L).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With 2 Consecutive Intact Parathyroid Hormone (iPTH)/120 Between 150 and 300 pg/mL","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With 2 Consecutive iPTH Reductions of at Least 30% From Baseline","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Hemoglobin: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.263"}]}]}]},{"type":"SECONDARY","title":"Hematocrit: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"5.066"}]}]}]},{"type":"SECONDARY","title":"Red Blood Cells: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.496"}]}]}]},{"type":"SECONDARY","title":"White Blood Cells (WBC) and Platelet Count: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"2.982"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"47.03"}]}]}]},{"type":"SECONDARY","title":"Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"2.6812"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.294","spread":"0.597"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.032","spread":"0.1276"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.059","spread":"0.1522"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.0322"}]}]}]},{"type":"SECONDARY","title":"Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactic Dehydrogenase (LDH), and Bone-Specific Alkaline Phosphatase (BSAP): Mean Change From Baseline to Final Visit","description":"n=subjects with evaluable Baseline and Post-baseline data for each parameter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.55","spread":"16.501"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.45","spread":"12.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"33.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.4","spread":"86.95"}]}]}]},{"type":"SECONDARY","title":"Bilirubin, Blood Urea Nitrogen (BUN), Uric Acid, Magnesium, Glucose, Cholesterol, Triglycerides, High Sensitivity C-Reactive Protein (hsCRP), Inorganic Phosphate, Corrected Calcium, and Creatinine: Mean Change From Baseline to Final Visit","description":"n=subjects with evaluable Baseline and Post-baseline data for each parameter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.032","spread":"0.3165"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.013","spread":"0.0785"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.056","spread":"0.3035"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"11.614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"1.245"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.082","spread":"0.3649"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.36","spread":"10.172"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.4","spread":"27.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"40.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.061","spread":"0.1967"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"1.188"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.421"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"1.592"}]}]}]},{"type":"SECONDARY","title":"Alkaline Phosphatase: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.8","spread":"117.34"}]}]}]},{"type":"SECONDARY","title":"Sodium, Potassium, Chloride, Bicarbonate: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.746"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"3.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"3.446"}]}]}]},{"type":"SECONDARY","title":"Total Protein and Albumin: Mean Change From Baseline to Final Visit","description":"n=subjects with evaluable Baseline and Post-baseline data for each parameter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.325"}]}]}]},{"type":"SECONDARY","title":"Fibroblast Growth Factor-23 (FGF-23), 1,25-Hydroxy Vitamin D, 25-Hydroxy Vitamin D, and Intact Parathyroid Hormone (iPTH): Mean Change From Baseline to Final Visit","description":"n=subjects with evaluable Baseline and Post-baseline data for each parameter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1990.7","spread":"3317.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.65","spread":"29.296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"10.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-437.5","spread":"491.83"}]}]}]},{"type":"SECONDARY","title":"Osteocalcin: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117.21","spread":"223.07"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events","description":"An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Potentially Clinically Significant Electrocardiogram (ECG) Findings","description":"12-lead ECGs were recorded after the subject had been in the supine position for at least 5 minutes. The number of subjects with potentially clinically significant ECG findings, as determined by the investigator, is presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Mean Change From Baseline to Final Visit","description":"Blood pressure was measured after the subject had been sitting for at least 3 minutes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"15.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"12.98"}]}]}]},{"type":"SECONDARY","title":"Heart Rate: Mean Change From Baseline to Final Visit","description":"Heart rate was measured after the subject had been sitting for at least 3 minutes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"17.43"}]}]}]},{"type":"SECONDARY","title":"Oral Body Temperature: Mean Change From Baseline to Final Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.338"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Potentially Clinically Significant Physical Examination Findings","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":13},"commonTop":["NAUSEA","PYREXIA","COUGH","ABDOMINAL PAIN","ABDOMINAL PAIN UPPER"]}}}